Published in J Exp Med on July 30, 2007
Follicular helper T cells are required for systemic autoimmunity. J Exp Med (2009) 4.25
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
The biology of intestinal immunoglobulin A responses. Immunity (2008) 3.18
Modulation of adaptive immunity with Toll-like receptors. Semin Immunol (2009) 2.56
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol (2010) 2.55
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol (2013) 2.49
Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol (2009) 2.43
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med (2011) 1.91
Immunoglobulin responses at the mucosal interface. Annu Rev Immunol (2011) 1.82
Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol (2012) 1.72
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev (2011) 1.70
Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol (2011) 1.67
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood (2007) 1.64
Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol (2009) 1.60
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Endoplasmic reticulum HSP90b1 (gp96, grp94) optimizes B-cell function via chaperoning integrin and TLR but not immunoglobulin. Blood (2008) 1.55
BAFF and selection of autoreactive B cells. Trends Immunol (2011) 1.36
Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol (2008) 1.35
Interferon-α accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum (2011) 1.29
Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc Natl Acad Sci U S A (2012) 1.28
Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.25
Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol (2014) 1.24
Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest (2011) 1.22
Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum (2008) 1.22
Innate control of B cell responses. Trends Immunol (2011) 1.21
Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol (2010) 1.19
BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol (2009) 1.18
Lupus nephritis: lessons from murine models. Nat Rev Rheumatol (2009) 1.18
Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol (2009) 1.16
Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun (2009) 1.15
TLR signaling in B-cell development and activation. Cell Mol Immunol (2012) 1.12
Immunostimulatory activity of haptenated proteins. Proc Natl Acad Sci U S A (2009) 1.10
Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol (2012) 1.10
Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol (2013) 1.09
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Targeting BAFF in autoimmunity. Curr Opin Immunol (2010) 1.08
Germinal centers and autoimmune disease in humans and mice. Immunol Cell Biol (2016) 1.08
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol (2011) 1.08
Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum (2010) 1.05
TLR4 signaling augments B lymphocyte migration and overcomes the restriction that limits access to germinal center dark zones. J Exp Med (2009) 1.04
B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.03
Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses. J Immunol (2013) 1.03
B cell-intrinsic TLR7 signaling is essential for the development of spontaneous germinal centers. J Immunol (2014) 1.03
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest (2011) 1.01
Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med (2009) 1.01
A new site-directed transgenic rheumatoid factor mouse model demonstrates extrafollicular class switch and plasmablast formation. Autoimmunity (2010) 1.01
Lupus nephritis: an overview of recent findings. Autoimmune Dis (2012) 1.00
B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol (2013) 0.97
IFNα Inducible Models of Murine SLE. Front Immunol (2013) 0.97
TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice. Proc Natl Acad Sci U S A (2014) 0.97
Facultative role for T cells in extrafollicular Toll-like receptor-dependent autoreactive B-cell responses in vivo. Proc Natl Acad Sci U S A (2011) 0.96
Reduced c-myc expression levels limit follicular mature B cell cycling in response to TLR signals. J Immunol (2009) 0.96
Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol (2009) 0.96
Interleukin-10 mediated autoregulation of murine B-1 B-cells and its role in Borrelia hermsii infection. PLoS One (2010) 0.94
The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol (2013) 0.93
IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol (2011) 0.93
Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93
FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood (2008) 0.93
The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity. Cell (2016) 0.93
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest (2015) 0.92
B-cell activating factor targeted therapy and lupus. Arthritis Res Ther (2012) 0.92
Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med (2017) 0.91
Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood (2013) 0.91
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. J Interferon Cytokine Res (2011) 0.91
Follicular dendritic cells in health and disease. Front Immunol (2012) 0.90
Systemic autoimmunity in BAFF-R-mutant A/WySnJ strain mice. Eur J Immunol (2008) 0.90
B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus. Autoimmune Dis (2013) 0.90
CD4+ T cells and CD40 participate in selection and homeostasis of peripheral B cells. J Immunol (2014) 0.90
Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation (2013) 0.89
Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? Clin Dev Immunol (2011) 0.87
The rationale for BAFF inhibition in systemic lupus erythematosus. Curr Rheumatol Rep (2012) 0.87
Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyn-deficient mice. Eur J Immunol (2010) 0.87
B-cell selection and the development of autoantibodies. Arthritis Res Ther (2012) 0.86
Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int (2011) 0.86
B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. Curr Opin Immunol (2015) 0.85
Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. Dis Model Mech (2014) 0.84
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia (2015) 0.84
Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. J Exp Med (2015) 0.84
Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res (2015) 0.84
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol (2015) 0.84
MyD88 is involved in myeloid as well as lymphoid hematopoiesis independent of the presence of a pathogen. Am J Blood Res (2013) 0.83
B cells in glomerulonephritis: focus on lupus nephritis. Semin Immunopathol (2007) 0.82
Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS). Biol Direct (2011) 0.82
Animal Models of Interferon Signature Positive Lupus. Front Immunol (2015) 0.81
TLR tolerance reduces IFN-alpha production despite plasmacytoid dendritic cell expansion and anti-nuclear antibodies in NZB bicongenic mice. PLoS One (2012) 0.81
Efficient B cell responses to Borrelia hermsii infection depend on BAFF and BAFFR but not TACI. Infect Immun (2013) 0.81
Defects in Germinal Center Selection in SLE. Front Immunol (2015) 0.81
Production of autoantibodies by murine B-1a cells stimulated with Helicobacter pylori urease through toll-like receptor 2 signaling. Infect Immun (2011) 0.81
Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. J Cell Mol Med (2009) 0.81
Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases. Adv Pharm Bull (2015) 0.81
Altered B cell signalling in autoimmunity. Nat Rev Immunol (2017) 0.80
Mechanisms of autoantibody production in systemic lupus erythematosus. Front Immunol (2015) 0.80
B cell activating factor (BAFF) and T cells cooperate to breach B cell tolerance in lupus-prone New Zealand Black (NZB) mice. PLoS One (2010) 0.80
Innate signals in mucosal immunoglobulin class switching. J Allergy Clin Immunol (2010) 0.80
Genetic Interaction between Lyn, Ets1, and Btk in the Control of Antibody Levels. J Immunol (2015) 0.80
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol (2008) 0.79
Investigations of a rabbit (Oryctolagus cuniculus) model of systemic lupus erythematosus (SLE), BAFF and its receptors. PLoS One (2009) 0.79
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science (2006) 6.47
A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature (2005) 6.31
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol (2006) 6.00
Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell (1993) 5.99
Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity (2006) 5.47
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 5.30
Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol (2005) 4.99
BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol (2001) 4.87
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
Interleukin 1: an immunological perspective. Annu Rev Immunol (1985) 4.09
Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol (2006) 3.44
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med (2005) 3.43
Regulation of the T-independent humoral response by TACI. Immunity (2001) 3.43
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Systemic lupus erythematosus. N Engl J Med (1994) 3.35
TACI and BAFF-R mediate isotype switching in B cells. J Exp Med (2005) 3.31
T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A (2002) 2.63
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol (2004) 2.54
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med (2006) 2.44
Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity (2006) 2.36
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol (2004) 2.08
The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol (2004) 1.95
Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science (2005) 1.81
IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol (2007) 1.62
TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol (2005) 1.56
Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol (2004) 1.53
The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol (2004) 1.47
Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol (2005) 1.47
TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol (2004) 1.47
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol (2006) 1.43
The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun (2005) 1.37
BAFF augments certain Th1-associated inflammatory responses. J Immunol (2005) 1.37
B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol (2005) 1.36
T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol (2004) 1.34
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol (1998) 1.32
A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol (2004) 1.29
Is IgG2a a good Th1 marker in mice? Immunol Today (1998) 1.26
Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells. J Immunol (2006) 1.19
The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol (2007) 1.18
BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol (2006) 1.16
The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol (2006) 1.16
B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther (2003) 1.15
Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis (2004) 1.13
Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol (2005) 1.08
Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev (2005) 1.04
The role of TALL-1 and APRIL in immune regulation. Trends Immunol (2001) 1.01
Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol (2006) 1.01
SLE: translating lessons from model systems to human disease. Trends Immunol (2005) 1.01
BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur J Immunol (2007) 1.01
CD40 ligation in B cell activation, isotype switching and memory development. Semin Immunol (1994) 0.99
Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann N Y Acad Sci (2005) 0.98
Antinuclear antibodies. Autoimmunity (2005) 0.98
Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev (2005) 0.98
Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev (2005) 0.97
Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci (2003) 0.94
Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol (2006) 0.94
Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology (2006) 0.91
Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. Int Immunol (2006) 0.87
Systemic lupus erythematosus--2005 annus mirabilis? Nat Clin Pract Rheumatol (2006) 0.84
Immunology. Discriminating microbe from self suffers a double toll. Science (2006) 0.82
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature (2009) 8.71
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity (2009) 7.69
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity (2008) 6.41
T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol (2008) 5.78
T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol (2004) 5.53
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol (2005) 4.99
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 3.96
In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med (2009) 3.78
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
Diet, gut microbiota and immune responses. Nat Immunol (2011) 3.66
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med (2004) 3.34
Functional roles for C5a receptors in sepsis. Nat Med (2008) 3.33
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 3.19
A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med (2002) 3.13
Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 3.04
TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity (2008) 3.03
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol (2007) 2.99
Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov (2007) 2.97
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity (2005) 2.97
Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 2.88
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest (2003) 2.87
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 2.77
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med (2012) 2.66
Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62
Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. Immunity (2009) 2.61
Control systems and decision making for antibody production. Nat Immunol (2010) 2.60
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol (2004) 2.54
CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol (2011) 2.54
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol (2003) 2.48
Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res (2011) 2.39
Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity (2013) 2.37
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest (2003) 2.35
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol (2006) 2.29
Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol (2009) 2.29
NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol (2007) 2.26
Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 2.21
Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol (2008) 2.19
Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med (2006) 2.10
Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol (2004) 2.10
Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity (2009) 2.09
Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol (2005) 2.08
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis (2012) 2.06
Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med (2010) 2.06
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
IL-21 induces the functional maturation of murine NK cells. J Immunol (2004) 2.00
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med (2008) 2.00
Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat Immunol (2007) 1.97
Functional subsets of mouse natural killer cells. Immunol Rev (2006) 1.95
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med (2012) 1.93
Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood (2009) 1.91
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood (2007) 1.85
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood (2002) 1.83
TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood (2004) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
The pre-metastatic niche: finding common ground. Cancer Metastasis Rev (2013) 1.82
Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron (2011) 1.76
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
The functional plasticity of T cell subsets. Nat Rev Immunol (2009) 1.74
Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol (2005) 1.73
The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem (2009) 1.73
Mcl-1 is essential for the survival of plasma cells. Nat Immunol (2013) 1.73